A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2017
At a glance
- Drugs CDX-0158 (Primary)
- Indications Gastrointestinal stromal tumours; Solid tumours
- Focus Adverse reactions
- Sponsors Celldex Therapeutics; Kolltan Pharmaceuticals
- 14 Mar 2017 Data from the study are expected by year-end 2017, as reported in Celldex Therapeutics media release
- 04 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 04 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.